Gefitinib - Wikipedia

Gefitinib (ZD1839) (INN, / ɡ ɛ ˈ f ɪ t ɪ n ɪ b /, trade name Iressa) is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor ...

Gefitinib (ZD1839) | EGFR inhibitor | Read Reviews ...

Gefitinib (Iressa) also known as ZD-1839 & Iressa is a novel potent EGFR tyrosine kinase phosphorylation inhibitor with IC50 of 37, 26 and 57 nM. Find all the ...

Gefitinib – Wikipedia

Wirkmechanismus. Gefitinib hemmt vor allem die Tyrosinkinasen aus der EGFR-Familie (Epidermal Growth Factor Receptor, Rezeptor für den Epidermiswachstumsfaktor).

Gefitinib or Chemotherapy for Non–Small- Cell Lung ...

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer n engl j med 362;25 nejm.org june 24, 2010 2381 N on–small-cell lung cancer is a

Iressa (gefitinib) Uses, Dosage, Side Effects - Drugs.com

Iressa is used in the treatment of non-small cell lung cancer. Learn about side effects, interactions and indications.

艾瑞莎膜衣錠 (Gefitinib) | 醫療財團法人辜 ...

學名：Gefitinib. 商品名：Iressa® Tablet. 中文名：艾瑞莎膜衣錠. 作用機轉：不是造成細胞直接的毒殺，而是對於癌症的發展生長 ...

Activating Mutations in the Epidermal Growth Factor ...

Background Most patients with non–small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor ...

Iressa 250mg film-coated tablets - Summary of Product ...

Each tablet contains 250 mg of gefitinib. Excipients with known effect: Each tablet contains 163.5 mg of lactose (as monohydrate). Each tablet contains 3.86 mg of sodium.

Erlotinib - Wikipedia

External links. Official Tarceva website; Tarceva Discussion Group for Cancer Patients; Sordella R, Bell DW, Haber DA, Settleman J (August 2004). "Gefitinib ...

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Interstitial lung disease (ILD)which may be acute in onset, has been observed in 1.3% of patients receiving gefitinib, and some cases have been fatal (see section4.8).